LON:EVG - Evgen Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 13.75 0.00 (0.00 %)
(As of 10/21/2018 08:43 AM ET)
Previous CloseGBX 13.75
Today's RangeGBX 13.50 - GBX 13.75
52-Week RangeGBX 12.15 - GBX 29.25
Volume154,579 shs
Average Volume207,445 shs
Market Capitalization£11.63 million
P/E RatioN/A
Dividend YieldN/A
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex for synthesizing and stabilizing the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.

Receive EVG News and Ratings via Email

Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Drug Manufacturers - Specialty & Generic


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-97.50%
Return on Assets-86.51%


Outstanding Shares74,110,000
Market Cap£11.63 million

Evgen Pharma (LON:EVG) Frequently Asked Questions

What is Evgen Pharma's stock symbol?

Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

What price target have analysts set for EVG?

3 Wall Street analysts have issued 1-year price targets for Evgen Pharma's shares. Their forecasts range from GBX 113 to GBX 113. On average, they anticipate Evgen Pharma's stock price to reach GBX 113 in the next year. This suggests a possible upside of 721.8% from the stock's current price. View Analyst Price Targets for Evgen Pharma.

What is the consensus analysts' recommendation for Evgen Pharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evgen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evgen Pharma.

Who are some of Evgen Pharma's key competitors?

Who are Evgen Pharma's key executives?

Evgen Pharma's management team includes the folowing people:
  • Dr. Stephen Franklin, CEO & Exec. Director
  • Mr. Richard Anthony Moulson, CFO & Exec. Director (Age 56)
  • Sally Ross, Clinical Devel. Officer
  • Ms. Liz Jenkins, Regulatory Consultant
  • Dr. Thomas Morris, Consultant & Medical Advisor of Oncology

How do I buy shares of Evgen Pharma?

Shares of EVG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Evgen Pharma's stock price today?

One share of EVG stock can currently be purchased for approximately GBX 13.75.

How big of a company is Evgen Pharma?

Evgen Pharma has a market capitalization of £11.63 million. Evgen Pharma employs 11 workers across the globe.

What is Evgen Pharma's official website?

The official website for Evgen Pharma is http://evgen.com/.

How can I contact Evgen Pharma?

Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532.

MarketBeat Community Rating for Evgen Pharma (LON EVG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  255
MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma and other stocks. Vote "Outperform" if you believe EVG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2018 by MarketBeat.com Staff

Featured Article: Google Finance Portfolio

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel